Fixed-Duration Venetoclax vs Continuous Ibrutinib in Untreated CLL: What the CLL17 Trial Means for Patients

n

Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults. Over the past decade, treatment has shifted from chemotherapy to targeted therapies such as BTK inhibitors and BCL-2 inhibitors. One important question has remained:

Is it better to treat CLL continuously, or can patients safely stop treatment after a fixed period?

The phase 3 CLL17 trial provides new answers. The study compared fixed-duration Venetoclax regimens with continuous Ibrutinib in previously untreated CLL. The results suggest that time-limited treatment may be just as effective — and in some ways even deeper — than continuous therapy.

Understanding the Treatment Approaches

What Is Continuous Ibrutinib?

Ibrutinib is a BTK (Bruton’s tyrosine kinase) inhibitor. It blocks signals that help CLL cells survive and grow. Traditionally, it is taken daily and continued indefinitely until disease progression or unacceptable side effects.

This means many patients remain on therapy for years.

What Is Fixed-Duration Venetoclax?

Venetoclax is a BCL-2 inhibitor. It helps trigger cancer cell death. In CLL17, venetoclax was given in combination regimens for a predefined period, after which treatment was stopped.

The fixed-duration regimens studied were:

• Venetoclax + Obinutuzumab
• Venetoclax + ibrutinib

The idea behind fixed-duration therapy is simple:

• Achieve a deep remission.
• Stop treatment.
• Allow patients a treatment-free interval.

What Was the CLL17 Trial?

The CLL17 trial was a large, randomized, phase 3 study (NCT04608318) involving 909 patients with previously untreated CLL.

Participants were assigned to one of three groups:

1. Venetoclax + obinutuzumab (fixed duration)
2. Venetoclax + ibrutinib (fixed duration)
3. Continuous ibrutinib alone

The primary goal was to compare progression-free survival (PFS).

Median follow-up was 34.2 months.

Key Results: Did Fixed-Duration Therapy Work?

Progression-Free Survival (PFS)

At 3 years:

• Venetoclax + obinutuzumab: 81.1%
• Venetoclax + ibrutinib: 79.4%
• Continuous ibrutinib: 81.0%

Both venetoclax-containing regimens met prespecified criteria for noninferiority compared with ibrutinib alone.

What Does “Noninferior” Mean?

It means that fixed-duration therapy was not inferior to continuous ibrutinib in preventing disease progression.

In other words:
Patients did just as well stopping therapy after a fixed course as they did staying on treatment continuously — at least within the follow-up period.

Overall Survival (OS)

Overall survival exceeded 90% across all study arms.

There was no meaningful difference in survival between groups at the time of analysis.

Deeper Remissions With Fixed-Duration Therapy

One of the most important findings of CLL17 involved minimal residual disease (MRD).

What Is MRD?

MRD measures whether very small amounts of leukemia cells remain in the blood after treatment. Achieving undetectable MRD is associated with deeper remissions and potentially longer remission duration.

In CLL17:

• 73.3% of patients treated with venetoclax + obinutuzumab achieved undetectable MRD in peripheral blood.
• 47.2% of patients receiving venetoclax + ibrutinib achieved undetectable MRD.
• No patients receiving ibrutinib alone achieved undetectable MRD.

This suggests that venetoclax-based fixed-duration therapy produced deeper responses than continuous ibrutinib.

Complete response rates were also higher with venetoclax combinations.

Safety and Side Effects

All treatments had side effects, but their patterns differed.

Most Common Side Effects Across All Groups

• Infections
• Gastrointestinal disorders
• Cytopenias (low blood counts)

Serious Adverse Events

Serious adverse events occurred most often in the venetoclax + obinutuzumab group (64.1%).

Rates were lower in:

• Venetoclax + ibrutinib: 46.9%
• Continuous ibrutinib: 47.7%

Severe infections, including grade 3 or higher COVID-19, were a major safety concern. Fatal infections accounted for most deaths across study arms.

Tumor Lysis Syndrome (TLS)

Tumor lysis syndrome was rare. It occurred mainly early in treatment, particularly after the first obinutuzumab infusion in the venetoclax-obinutuzumab group.

With proper monitoring and dose ramp-up, TLS risk was manageable.

Cardiac Toxicity

Continuous ibrutinib was associated with more heart-related side effects, including:

• Atrial fibrillation
• Hypertension
• Serious cardiac events
• Cardiovascular deaths

This is an important consideration, especially for older patients or those with heart disease.

Treatment Discontinuation

Early treatment discontinuation occurred more often with continuous ibrutinib (33.2%) compared with:

• Venetoclax + ibrutinib: 22.1%
• Venetoclax + obinutuzumab: 14.6%

Most discontinuations were due to adverse events or other illnesses.

Who Was Included in the Study?

The study population included higher-risk patients:

• 56.6% had unmutated IGHV
• 7.6% had del(17p) or TP53 mutations
• 19.2% had a complex karyotype
• Over 60% were high or very high risk according to the CLL International Prognostic Index

This makes the results especially relevant to patients with higher-risk disease.

What Does This Mean for Patients?

The CLL17 trial provides strong evidence that fixed-duration venetoclax-based therapy is not inferior to continuous ibrutinib in untreated CLL.

For patients, this means:

• A time-limited treatment option is available.
• Many patients can stop therapy after achieving deep remission.
• Progression-free survival remains comparable.
• Deeper MRD responses may offer longer remission periods.
• Continuous exposure to long-term side effects may be reduced.

The possibility of treatment-free intervals is a major quality-of-life advantage.

How Should Patients Think About Their Options?

Treatment choice depends on many factors:

• Age and overall health
• Cardiovascular risk
• Kidney function
• Risk of tumor lysis syndrome
• Genetic risk markers (TP53, IGHV status)
• Personal preference regarding continuous vs time-limited therapy

Some patients may prefer:

• Continuous therapy with simpler monitoring.
  Others may prefer:
• Fixed-duration therapy with the goal of stopping treatment.

Both approaches are supported by strong clinical data.

Conclusion

The phase 3 CLL17 trial shows that fixed-duration venetoclax combinations match continuous ibrutinib in progression-free survival for untreated CLL. At the same time, venetoclax-based regimens achieved higher rates of undetectable MRD and allowed patients to stop therapy after a defined period.

For many patients, fixed-duration therapy may offer similar effectiveness with the added benefit of treatment-free intervals.

As always, treatment decisions should be made in discussion with a hematologist or oncology team, taking into account individual risk factors and preferences.

The CLL17 results mark an important step toward more personalized and flexible treatment strategies in chronic lymphocytic leukemia.

References

1. Al-Sawaf O, Stumpf J, Zhang C, et al; CLL17 Trial Investigators.
   Fixed-duration versus continuous treatment for chronic lymphocytic leukemia.
   The New England Journal of Medicine. Published online December 6, 2025.
   https://www.nejm.org/doi/10.1056/NEJMoa2515458
2. Rare Disease Advisor.
   Fixed-Duration Venetoclax Noninferior to Continuous Ibrutinib in Untreated CLL.
   https://www.rarediseaseadvisor.com/news/fixed-duration-venetoclax-matches-continuous-ibrutinib-untreated-cll/
3. ClinicalTrials.gov.
   CLL17 Trial (NCT04608318): Fixed-Duration vs Continuous Treatment in Previously Untreated CLL.
   https://clinicaltrials.gov/study/NCT04608318